Cargando…

Pharmaceutical pricing, cost containment and new treatments for rare diseases in children

Cost-containment in healthcare spending has become a central issue in public policy and healthcare reform, especially as the affordable care act adds millions of people to public and private insurance rolls. In this climate, longstanding criticism of pharmaceutical pricing has grown sharper, and man...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stella, Peter, Gold-von Simson, Gabrielle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Position Statement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221662/ https://www.ncbi.nlm.nih.gov/pubmed/25348640 http://dx.doi.org/10.1186/s13023-014-0152-2

Ejemplares similares

Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases
por: Douglas, Conor M. W., et al.
Publicado: (2022)

Sharing is caring: a call for a new era of rare disease research and development
por: Denton, Nathan, et al.
Publicado: (2022)

From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research
por: Kaufmann, Petra, et al.
Publicado: (2018)

The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force
por: Southall, Noel T, et al.
Publicado: (2019)

A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
por: Cui, Yazhou, et al.
Publicado: (2015)

TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases
por: Annemans, Lieven, et al.
Publicado: (2020)

Steroid hormone analysis in diagnosis and treatment of DSD: position paper of EU COST Action BM 1303 ‘DSDnet’
por: Kulle, A, et al.
Publicado: (2017)

European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT)
por: Eker, Omer F., et al.
Publicado: (2020)

Epidemiology of rare diseases in Brazil: protocol of the Brazilian Rare Diseases Network (RARAS-BRDN)
por: Félix, Têmis Maria, et al.
Publicado: (2022)

Compounded medication for patients with rare diseases
por: Dooms, Marc, et al.
Publicado: (2018)

Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER
por: Bernts, Lucas H. P., et al.
Publicado: (2019)

Rare diseases in Tanzania: a National Call for Action to address policy and urgent needs of individuals with rare diseases
por: Kaywanga, Frida, et al.
Publicado: (2022)

eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
por: Paglialonga, Alessia, et al.
Publicado: (2021)

Rare disease education in Europe and beyond: time to act
por: Tumiene, Birute, et al.
Publicado: (2022)

Pharmacists are initiators in palliative care for patients with rare diseases
por: Dooms, M.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

European Reference networks for rare diseases: what is the conceptual framework?
por: Héon-Klin, Véronique
Publicado: (2017)

A patient advocating for transparent science in rare disease research
por: Yang, Richard Rui
Publicado: (2023)

European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants
por: van de Laar, Ingrid M. B. H., et al.
Publicado: (2019)

Electronic cigarettes: A position statement from the Thoracic Society of Australia and New Zealand*
por: McDonald, Christine F., et al.
Publicado: (2020)

Increasing African genomic data generation and sharing to resolve rare and undiagnosed diseases in Africa: a call-to-action by the H3Africa rare diseases working group
por: Lumaka, Aimé, et al.
Publicado: (2022)

Rare diseases in Chile: challenges and recommendations in universal health coverage context
por: Encina, Gonzalo, et al.
Publicado: (2019)

Data silos are undermining drug development and failing rare disease patients
por: Denton, Nathan, et al.
Publicado: (2021)

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases
por: Corben, Louise A., et al.
Publicado: (2022)

European expert network on rare communicable diseases and other rare diseases linked to mobility and globalisation focused on health care provision (EURaDMoG): a feasibility study
por: Requena-Méndez, Ana, et al.
Publicado: (2020)

Ventilatory support at home for children: A joint position paper from the Thoracic Society of Australia and New Zealand/Australasian Sleep Association
por: Chawla, Jasneek, et al.
Publicado: (2021)

Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*
por: Dummer, Jack, et al.
Publicado: (2020)

The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks
por: Evangelista, Teresinha, et al.
Publicado: (2016)

Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
por: Kourakis, Stephanie, et al.
Publicado: (2021)

Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
por: Mulberg, Andrew E., et al.
Publicado: (2019)

The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement
por: Black, Graeme C., et al.
Publicado: (2021)

European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
por: Shovlin, Claire L., et al.
Publicado: (2018)

RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework
por: Bellgard, Matthew I., et al.
Publicado: (2019)

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
por: Annemans, Lieven, et al.
Publicado: (2017)

Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic
por: Brizola, E., et al.
Publicado: (2020)

Integrating rare disease management in public health programs in India: exploring the potential of National Health Mission
por: Choudhury, Mohua Chakraborty, et al.
Publicado: (2022)

Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium
por: Rudebeck, Mattias, et al.
Publicado: (2021)

Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients
por: Zanello, Galliano, et al.
Publicado: (2022)

Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force
por: Nabbout, Rima, et al.
Publicado: (2023)

Diabetes Management at Camps for Children With Diabetes
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bg3c9vrbqjp9jgosano9au5ku4